The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk

作者：Amato Marco Calogero; Verghi Monica; Galluzzo Aldo; Giordano Carla^*

来源：Human Reproduction, 2011, 26(6): 1486-1494.

DOI：10.1093/humrep/der088

• polycystic ovary syndrome
• visceral adiposity index
• visceral obesity
• oligomenorrhea
• cardiometabolic risk

Background: Women with polycystic ovary syndrome (PCOS) frequently exhibit central obesity, glucose intolerance, atherogenic dyslipidemia and hypertension, which are characteristic features of a condition of cardiometabolic risk. Our objective was to investigate the relationship between visceral adiposity index (VAI) and phenotypic characteristics in women with PCOS.
Methods: We conducted a cross-sectional case-control study in our Endocrinology Outpatients Clinic. A total of 220 women with PCOS (Rotterdam definition) and 144 age-and BMI-matched healthy women were studied. We evaluated hyperandrogenemia and clinical hyperandrogenism, ovarian morphology, hypothalamic-hypophyseal axis and metabolic syndrome parameters. An oral glucose tolerance test (75 g glucose) measured areas under the curve (AUC) for insulin (AUC(2h-insulin)) and for glucose (AUC(2h-glucose)). Homeostasis model assessment of insulin resistance, the Matsuda index of insulin resistance and VAI were determined.
Results: Of all the variables examined, at multivariate analysis, only AUC(2h-insulin) [odds ratio (OR): 1.00; 95% confidence interval (Cl): 1.00-1.00; P = 0.003] and VAI score (OR: 1.81; 95% Cl: 1.20-2.73; P = 0.005) showed an independent association with PCOS. All phenotypes with oligomenorrhea showed a higher VAI score than the control group (oligomenorrhea + hyperandrogenism: 2.49 +/- 1.46 versus 1.62 +/- 0.84, P < 0.001; oligomenorrhea + polycystic ovary morphology: 2.25 +/- 1.4 versus 1.62 +/- 0.84, P = 0.001; complete phenotype: 2.45 +/- 1.63 versus 1.62 +/- 0.84, P < 0.001).
Conclusions: Our data suggest that VAI could be an easy and useful tool in daily clinical practice and in population studies for the assessment of cardiometabolic risk associated with PCOS.

• 出版日期2011-6